Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves
Sun-Young Kim, Joshua A Salomon, Sue J Goldie
Volume 85, Number 11, November 2007, 833-842
Table 4. Base case results discounted at 3% for a birth cohort of 56 000 infants, assuming 94% coverage of hepatitis B virus (HBV) vaccine
| Strategy | Total no. cases of new infectionsa | Total no. cases of primary liver cancera | Total no. cases of premature deathsa | Costb | Incrementalcostb | Effectivenessc | Incrementaleffectivenessd | Incremental cost–effectiveness ratioe |
|---|---|---|---|---|---|---|---|---|
| No vaccination | 41 245 | 155 | 161 | 134 400 | – | 295 266 | – | – |
| Routine infant vaccination | 12 119 | 21 | 29 | 243 600 | 109 760 | 291 385 | 3 881 | 28 |
| No vaccination | 41 245 | 155 | 161 | 0 | – | 295 266 | 0 | |
| Routine infant vaccination | 12 119 | 21 | 29 | 182 000 | 182 000 | 291 385 | 3 881 | 47 |
a Epidemiological outcomes do not vary by perspective.b All costs in 2002 US$.c Effectiveness measured in disability-adjusted life years.d Incremental effectiveness measured in disability-adjusted life years averted.e The incremental cost–effectiveness ratio is the ratio of dollars per disability-adjusted life year averted.